ArticleBMC urology2025

Docetaxel versus androgen receptor pathway inhibitors as first-line therapy for metastatic castration-resistant prostate cancer after doublet therapy: a multicenter retrospective study from Saudi Arabia.

Shouki Bazarbashi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.